Novo Nordisk, the Danish pharmaceutical giant, has announced slower growth projections for the upcoming year, following a remarkable doubling of sales for its obesity drug Wegovy in the final quarter of 2024. Although growth is predicted to decelerate to between 16% and 24%, this still aligns with, and even surpasses, some analyst expectations.
About the Author
